Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT00033709
Other study ID # CDR0000069314
Secondary ID CPMC-IRB-14323NC
Status Active, not recruiting
Phase Phase 2
First received April 9, 2002
Last updated January 3, 2014
Start date March 2002

Study information

Verified date May 2005
Source National Cancer Institute (NCI)
Contact n/a
Is FDA regulated No
Health authority United States: Federal Government
Study type Interventional

Clinical Trial Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. Combining temozolomide with thalidomide may kill more tumor cells.

PURPOSE: Phase II trial to study the effectiveness of combining temozolomide with thalidomide in treating patients who have metastatic, locally advanced, or unresectable leiomyosarcoma.


Description:

OBJECTIVES:

- Determine the efficacy of temozolomide and thalidomide in patients with metastatic, locally advanced, or unresectable leiomyosarcoma.

- Determine the time to progression in patients treated with this regimen.

- Determine the overall survival of patients treated with this regimen.

- Determine the clinical and laboratory toxic effects and tolerability of this regimen in these patients.

OUTLINE: Patients receive oral temozolomide once daily for 7 days every other week and oral thalidomide once daily. Treatment continues for up to 26 weeks in the absence of disease progression or unacceptable toxicity.

PROJECTED ACCRUAL: A total of 15-25 patients will be accrued for this study within 7.5-25 months.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 0
Est. completion date
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility DISEASE CHARACTERISTICS:

- Histologically confirmed leiomyosarcoma

- Metastatic, locally advanced, or unresectable

- Ineligible for other high priority national or institutional study

- At least 1 unidimensionally measurable lesion documented on radiologic study

- At least 2 cm by 2 cm

- Not previously irradiated unless disease progression at the site is evident

- No brain metastases

PATIENT CHARACTERISTICS:

Age:

- 18 and over

Performance status:

- SWOG 0-2

Life expectancy:

- More than 2 months

Hematopoietic:

- WBC greater than 3,000/mm^3

- Neutrophil count at least 1,500/mm^3

- Platelet count greater than 70,000/mm^3

- Hemoglobin at least 10 g/dL

Hepatic:

- Bilirubin less than upper limit of normal (ULN)

- SGOT or SGPT less than 1.5 times ULN*

- Alkaline phosphatase less than 2 times ULN* NOTE: * Less than 5 times ULN if documented liver disease

Renal:

- Creatinine less than 1.5 times normal OR

- Creatinine clearance greater than 60 mL/min

- BUN less than 1.5 times normal

Other:

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use 2 forms of effective contraception for 4 weeks before, during, and for 4 weeks after study therapy

- No acute infection requiring systemic antibiotics

- No frequent vomiting or medical condition that would preclude intake of oral medication (e.g., partial bowel obstruction)

- No other serious medical or psychiatric illness that would preclude study participation

- No prior malignancy except curatively treated carcinoma in situ of the cervix or skin cancer

PRIOR CONCURRENT THERAPY:

Biologic therapy:

- Not specified

Chemotherapy:

- At least 4 weeks since prior chemotherapy

- No more than 3 prior systemic chemotherapy regimens for metastatic, locally advanced, or unresectable leiomyosarcoma

- Prior dacarbazine allowed

Endocrine therapy:

- Not specified

Radiotherapy:

- See Disease Characteristics

- At least 4 weeks since prior radiotherapy

- No prior radiotherapy to 50% or more of bone marrow

- Concurrent radiotherapy for local control or palliative therapy for painful bony or soft tissue lesion allowed

Surgery:

- At least 4 weeks since prior surgery and recovered

Other:

- Recovered from all prior therapies

- No other concurrent investigational drugs

Study Design

Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
temozolomide

thalidomide


Locations

Country Name City State
United States Herbert Irving Comprehensive Cancer Center at Columbia University New York New York

Sponsors (2)

Lead Sponsor Collaborator
Herbert Irving Comprehensive Cancer Center National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

References & Publications (1)

Boyar M, Keohan ML, Hesdorffer M, et al.: Phase II study of temozolomide and thalidomide in patients with unresectable or metastatic leiomyosarcoma. [Abstract] J Clin Oncol 23 (Suppl 16): A-9029, 823s, 2005.

Outcome

Type Measure Description Time frame Safety issue
Primary Response (complete and partial response) No
Secondary Time to progression No
Secondary Overall survival No
Secondary Clinical benefit No
See also
  Status Clinical Trial Phase
Recruiting NCT04457258 - 68Ga-FAPi-46 PET/CT Scan in Imaging Patients With Sarcoma Early Phase 1
Recruiting NCT04986748 - Using QPOP to Predict Treatment for Sarcomas and Melanomas
Completed NCT04474678 - Quality Improvement Project - "My Logbook! - I Know my Way Around!"; ("Mein Logbuch - Ich Kenne Mich Aus!") N/A
Recruiting NCT05415098 - Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas Phase 1
Recruiting NCT04535713 - GALLANT: Metronomic Gemcitabine, Doxorubicin, Docetaxel and Nivolumab for Advanced Sarcoma Phase 2
Completed NCT03521531 - Burden and Medical Care of Sarcoma in Germany
Completed NCT02496520 - Dendritic Cell-based Immunotherapy for Advanced Solid Tumours of Children and Young Adults Phase 1/Phase 2
Terminated NCT02054104 - Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum Phase 1/Phase 2
Terminated NCT00788125 - Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT04577014 - Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma Phase 1/Phase 2
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Completed NCT04052334 - Lymphodepletion Plus Adoptive Cell Therapy With High Dose IL-2 in Adolescent and Young Adult Patients With Soft Tissue Sarcoma Phase 1
Completed NCT01593748 - A Phase II Trial Comparing Gemcitabine and Pazopanib Versus Gemcitabine and Docetaxel for Patients With Advanced Soft Tissue Sarcoma Phase 2
Completed NCT00199849 - NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine Phase 1
Recruiting NCT04367779 - Research of Biomarkers of Response to Proton Beam Therapy in Pediatric and Adult Patients.
Completed NCT01879085 - Study of Vorinostat in Combination With Gemcitabine and Docetaxel in Advanced Sarcoma Phase 1/Phase 2
Recruiting NCT04553692 - Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants With Relapsed, Refractory, or Newly Diagnosed Cancers Phase 1
Completed NCT01209598 - PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma Phase 2
Completed NCT04553471 - Palliative Lattice Stereotactic Body Radiotherapy (SBRT) for Patients With Sarcoma, Thoracic, Abdominal, and Pelvic Cancers N/A
Withdrawn NCT04906876 - A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas Phase 2